Financials in USD. Standardized financial statements.
A compact view of how Applied Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $455,000 | $9.99M | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -95.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $48.74M | $53.91M | $441,000 | $0 | $0 | $23,000 | $0 | $0 |
| Gross Profit? | -$48.29M | -$43.91M | -$441,000 | $0 | $0 | -$23,000 | $0 | $0 |
| Gross Margin? | -10613.0% | -439.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $56.01M | $20.62M | $82.51M | $105.62M | $94.47M | $45.56M | $13.52M | $4.29M |
| Operating Income? | -$104.30M | -$64.53M | -$82.95M | -$105.62M | -$94.47M | -$45.58M | -$13.52M | -$4.29M |
| EBITDA? | -$104.30M | -$64.53M | -$82.07M | -$105.62M | -$94.47M | -$45.49M | -$3.00M | $3,000 |
| Income Before Tax | -$105.62M | -$119.76M | -$82.51M | -$105.58M | -$93.96M | -$45.51M | -$16.52M | -$4.28M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$105.62M | -$119.76M | -$82.51M | -$105.58M | -$93.96M | -$45.51M | -$16.52M | -$4.28M |
| EPS? | $-0.76 | $-1.42 | $-2.18 | $-4.12 | $-4.28 | $-3.55 | $-1.80 | $-0.47 |
| Diluted EPS? | $-0.76 | $-1.42 | $-2.18 | $-4.12 | $-4.28 | $-3.55 | $-1.80 | $-0.47 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality